EPS for AmpliPhi Biosciences Corporation (APHB) Expected At $-0.20

July 14, 2018 - By Kristin Houston

AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) Logo

Analysts expect AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) to report $-0.20 EPS on August, 13.They anticipate $0.58 EPS change or 74.36 % from last quarter’s $-0.78 EPS. After having $-0.24 EPS previously, AmpliPhi Biosciences Corporation’s analysts see -16.67 % EPS growth. The stock decreased 0.79% or $0.009 during the last trading session, reaching $1.091. About 28,691 shares traded. AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) has risen 59.19% since July 14, 2017 and is uptrending. It has outperformed by 46.62% the S&P500.

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage technology. The company has market cap of $18.00 million. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. It currently has negative earnings. The firm has reported results from two Phase I clinical trials of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients, as well as evaluating the safety of AB-SA01 when administered topically to the intact skin of healthy adults.

AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.